MAP kinases in lung endothelial permeability induced by microtubule disassembly.

TitleMAP kinases in lung endothelial permeability induced by microtubule disassembly.
Publication TypeJournal Article
Year of Publication2005
AuthorsBirukova AA, Birukov KG, Gorshkov B, Liu F, Garcia JGN, Verin AD
JournalAm J Physiol Lung Cell Mol Physiol
Date Published2005 Jul
ISSN Number1040-0605
KeywordsActins, Actomyosin, Animals, Antineoplastic Agents, Butadienes, Capillary Permeability, Cattle, Cells, Cultured, Endothelial Cells, Endothelium, Vascular, Enzyme Inhibitors, Humans, Imidazoles, Lung, MAP Kinase Signaling System, Microtubules, Nitriles, Protein Kinases, Pyridines

<p>Lung endothelial barrier function is regulated by multiple signaling pathways, including mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinases (ERK) 1/2 and p38. We have recently shown involvement of microtubule (MT) disassembly in endothelial cell (EC) barrier failure. In this study, we examined potential involvement of ERK1/2 and p38 MAPK in lung EC barrier dysfunction associated with MT disassembly. MT inhibitors nocodazole (0.2 microM) and vinblastine (0.1 microM) induced sustained activation of Ras-Raf-MEK1/2-ERK1/2 and MKK3/6-p38-MAPKAPK2 MAPK cascades in human and bovine pulmonary EC, as detected by phosphospecific antibodies and in MAPK activation assays. These effects were linked to increased permeability assessed by measurements of transendothelial electrical resistance and cytoskeletal remodeling analyzed by morphometric analysis of EC monolayers. MT stabilization by taxol (5 microM, 1 h) attenuated nocodazole-induced ERK1/2 and p38 MAPK activation and phosphorylation of p38 MAPK substrate 27-kDa heat shock protein and regulatory myosin light chains, the proteins involved in actin polymerization and actomyosin contraction. Importantly, only pharmacological inhibition of p38 MAPK by SB-203580 (20 microM, 1 h) attenuated nocodazole-induced MT depolymerization, actin remodeling, and EC barrier dysfunction, whereas the MEK/ERK1/2 inhibitor U0126 (5 microM, 1 h) exhibited no effect. These data suggest a direct link between p38 MAPK activation, remodeling of MT network, and EC barrier regulation.</p>

Alternate JournalAm. J. Physiol. Lung Cell Mol. Physiol.
PubMed ID15778245
Grant ListHL-58064 / HL / NHLBI NIH HHS / United States
HL-67307 / HL / NHLBI NIH HHS / United States
HL-68062 / HL / NHLBI NIH HHS / United States